ATE275970T1 - Impfstoffzusammensetzungen - Google Patents
ImpfstoffzusammensetzungenInfo
- Publication number
- ATE275970T1 ATE275970T1 AT94928455T AT94928455T ATE275970T1 AT E275970 T1 ATE275970 T1 AT E275970T1 AT 94928455 T AT94928455 T AT 94928455T AT 94928455 T AT94928455 T AT 94928455T AT E275970 T1 ATE275970 T1 AT E275970T1
- Authority
- AT
- Austria
- Prior art keywords
- double mutant
- antigen
- substituted
- manufacture
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 3
- 230000003000 nontoxic effect Effects 0.000 abstract 3
- 108010081690 Pertussis Toxin Proteins 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 241000588832 Bordetella pertussis Species 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939320454A GB9320454D0 (en) | 1993-10-05 | 1993-10-05 | Vaccine compositions |
GB939324743A GB9324743D0 (en) | 1993-12-02 | 1993-12-02 | Adjuvant compositions |
PCT/GB1994/002152 WO1995009649A1 (en) | 1993-10-05 | 1994-10-04 | Vaccine compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE275970T1 true ATE275970T1 (de) | 2004-10-15 |
Family
ID=26303633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94928455T ATE275970T1 (de) | 1993-10-05 | 1994-10-04 | Impfstoffzusammensetzungen |
Country Status (7)
Country | Link |
---|---|
US (2) | US7169399B2 (de) |
EP (1) | EP0725653B2 (de) |
AT (1) | ATE275970T1 (de) |
AU (1) | AU7788194A (de) |
DE (1) | DE69434000T3 (de) |
DK (1) | DK0725653T3 (de) |
WO (1) | WO1995009649A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
AU7788194A (en) | 1993-10-05 | 1995-05-01 | Medeva Holdings B.V. | Vaccine compositions |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) * | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
CN1607941A (zh) * | 2001-11-19 | 2005-04-20 | 贝克顿迪肯森公司 | 粒状药物组合物 |
EP1790358A1 (de) * | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Proteinkonstrukte designed zum Targeting und Lyse von Zellen |
MX343356B (es) | 2010-03-30 | 2016-11-03 | Pfenex Inc * | Toxinas proteicas recombinantes de alto nivel de expresion. |
CN104024400B (zh) * | 2011-12-21 | 2018-02-16 | 亚洲生物网有限公司 | 经修饰的百日咳博德特氏菌菌株 |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
US9452213B2 (en) | 2014-07-15 | 2016-09-27 | Inventprise, Llc | Genetically detoxified pertussis vaccine that maintains intrinsic adjuvant activity |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8727489D0 (en) * | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
WO1989010976A1 (en) | 1988-05-05 | 1989-11-16 | The Public Health Research Institute Of The City O | Protease-deficient gram-positive bacteria and their use as host organisms for the production of recombinant products |
AP8900132A0 (en) * | 1988-07-22 | 1991-01-14 | Smithkline Biolog | Bordetella pertussis vaccine |
EP0396964B1 (de) | 1989-04-28 | 1995-09-06 | SCLAVO S.p.A. | Pertussistoxin-Mutanten, dieselbe produzierende Bordetella-Stämme und ihre Verwendung als Vakzin gegen Pertussis |
US5601826A (en) * | 1989-06-30 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide which produces protective immunity against tetanus |
EP0425082B1 (de) | 1989-09-04 | 1995-04-26 | Evans Medical Limited | Vakzine gegen Bordetella |
JPH03135923A (ja) * | 1989-10-20 | 1991-06-10 | Chemo Sero Therapeut Res Inst | 百日咳毒素bオリゴマーの構成サブユニットを含有する経鼻接種ワクチン |
IT1248735B (it) | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
EP0484621A3 (en) | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
CA2083553A1 (en) | 1991-11-25 | 1993-05-26 | Kuniharu Seki | Immunogen composition |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
AU7788194A (en) | 1993-10-05 | 1995-05-01 | Medeva Holdings B.V. | Vaccine compositions |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) * | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
BR9914160A (pt) | 1998-09-30 | 2001-06-26 | American Cyanamid Co | Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante |
-
1994
- 1994-10-04 AU AU77881/94A patent/AU7788194A/en not_active Abandoned
- 1994-10-04 WO PCT/GB1994/002152 patent/WO1995009649A1/en active IP Right Grant
- 1994-10-04 DE DE69434000T patent/DE69434000T3/de not_active Expired - Fee Related
- 1994-10-04 AT AT94928455T patent/ATE275970T1/de not_active IP Right Cessation
- 1994-10-04 DK DK94928455T patent/DK0725653T3/da active
- 1994-10-04 EP EP94928455A patent/EP0725653B2/de not_active Expired - Lifetime
-
2001
- 2001-02-02 US US09/775,909 patent/US7169399B2/en not_active Expired - Fee Related
-
2007
- 2007-01-09 US US11/651,346 patent/US20100255033A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0725653A1 (de) | 1996-08-14 |
WO1995009649A1 (en) | 1995-04-13 |
AU7788194A (en) | 1995-05-01 |
DE69434000D1 (de) | 2004-10-21 |
US20100255033A1 (en) | 2010-10-07 |
DK0725653T3 (da) | 2004-10-11 |
DE69434000T3 (de) | 2008-11-06 |
US7169399B2 (en) | 2007-01-30 |
EP0725653B2 (de) | 2008-04-02 |
EP0725653B1 (de) | 2004-09-15 |
DE69434000T2 (de) | 2005-01-27 |
US20010018056A1 (en) | 2001-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUT77869A (hu) | Nemtoxikus orális adjuvánsként használható mutáns enterotoxin | |
DE69434000D1 (de) | Impfstoffzusammensetzungen | |
UA40596C2 (uk) | Композиція вакцини та спосіб її одержання | |
GB9419979D0 (en) | Vaccine compositions | |
NZ323973A (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
IS3753A7 (is) | Endurbætt aðferð og samsetning bóluefnis | |
HK1121382A1 (en) | Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines | |
GB9209118D0 (en) | Vaccine compositions | |
HUP9801223A2 (hu) | Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel | |
DE69317435T2 (de) | Entzündungshemmende tolerogene und inmonoinhibitorische eigenschaften von karbohyhydrate bindenden peptiden | |
ZA918876B (en) | Avirulent microbes and uses therefor:salmonella typhi | |
FR2693655B1 (fr) | Vaccin antirabique avirulent. | |
GB9500788D0 (en) | Vaccine compositions | |
HK1025220A1 (en) | Novel saponin compositions and uses thereof | |
EA200300557A1 (ru) | Комбинированные композиции адъювантов | |
CA2388054A1 (en) | Compositions and methods for stimulating an immune response against infectious agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |